- Home
- INFQ vs JANX Comparison
INFQ vs JANX Comparison
Compare INFQ & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.12
HOLD
Current Price
$13.51
Company Overview
Basic Information| Metric | INFQ | JANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 740.3M | 790.3M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INFQ | JANX |
|---|---|---|
| Price | $10.12 | $13.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.60 |
| AVG Volume (30 Days) | ★ 2.5M | 784.8K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $209.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.61 | $12.12 |
| 52 Week High | $13.70 | $35.34 |
Technical Indicators
Market Signals| Indicator | INFQ | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 35.69 | 46.12 |
| Support Level | N/A | $13.01 |
| Resistance Level | $12.35 | $13.79 |
| Average True Range (ATR) | 0.88 | 0.55 |
| MACD | -0.16 | 0.07 |
| Stochastic Oscillator | 4.07 | 37.58 |
Price Performance
Historical Comparison INFQ
JANX
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.